Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 11
  • Journal CiteScore: 0.91
  • Journal Impact Factor: 0.6
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Cancer-upregulated gene-2 (CUG2) increases the protein stability of enhancer of zeste homolog (EZH2) by negatively regulating the beta-TrCP-mediated degradation

International Conference on Cancer Epigenetics and Biomarkers
October 26-28, 2017 Osaka, Japan

Yeongmi Cheon, Seyeong Jeon and Soojin Lee

Chungnam National University, South Korea

Posters & Accepted Abstracts: Arch Can Res

Abstract:

Enhancer of zeste homolog-2 (EZH2) is a component of the polycomb repressive complex-2 (PRC2), which mediates the gene silencing through trimethylation of histone H3 on lysine 27 (H3K27). Several studies reported that EZH2 overexpression is commonly found in diverse malignancies including prostate and breast cancer. Beta-TrCP is a substrate-recognition subunit of SCFbeta-TrCP ubiquitin ligase and it is reported that EZH2 is another interactor of beta-TrCP as a substrate of SCF complex. On the other hand, our recent study found that cancer-upregulated gene 2 (CUG2), which was originally identified as a putative proto-oncogene and is frequently overexpressed in various tumors, interacts with and stabilizes the protein level of EZH2. In this study, we show that EZH2 protein is destabilized by beta-TrCP overexpression and recovered by CUG2 co-expression. Moreover, we found that CUG2 binds to beta-TrCP and the protein level of beta-TrCP is decreased in CUG2-overexpressed cells, suggesting that CUG2 may increase EZH2 protein stability through negative regulation of beta-TrCP-mediated EZH2 degradation. Previously, it is reported that both of CUG2 and EZH2 possess putative nuclear localization signal (NLS) and are predominantly located in the nucleus. In this study, we also demonstrate that CUG2 may mediate the nuclear translocation of beta-TrCP, proposing that CUG2 may regulate the activity of SCFbeta-TrCP ubiquitin ligase in the nucleus. These findings suggest that CUG2 may negatively regulate the beta-TrCP-mediated EZH2 protein turnover in the nucleus and be involved in EZH2induced tumorigenesis.

Biography :

Yeongmi Cheon has obtained her Master’s degree at Chungnam National University, South Korea. Presently she is pursuing PhD in Molecular Biotechnology at Department of Bioscience and Biotechnology, Chungnam Graduate School.